NYSEAMERICAN:BTXBioTime Stock Price, Forecast & News

$0.91

0.00 (0.00 %)

(As of 06/4/2020 11:59 AM ET)

Add

Compare

Today's Range

$0.90

Now: $0.91▼

$0.95

50-Day Range N/A

52-Week Range

$0.66

Now: $0.91▼

$2.81

Volume772,201 shs

Average Volume719,479 shs

Market Capitalization$136.18 million

P/E RatioN/A

Dividend YieldN/A

BetaN/A

BioTime, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing therapies for the treatment of degenerative diseases in the United States and internationally. The company's lead product candidates include OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa multicenter trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also develops Renevia, a facial aesthetics product that is in pivotal clinical trial for the treatment of HIV-associated facial lipoatrophy; ReGlyde, a HyStem product in preclinical development as a device for viscosupplementation, and as a platform for intraarticular drug delivery in osteoarthritis; and Premvia, a Hystem Hydrogel product, as well as develop bone grafting products for the orthopedic diseases and injuries. In addition, it markets GeneCards, a human gene database; MalaCards, a human disease database; and Hextend, a plasma volume expander used to treat or prevent hypovolemia, including albumin, generic 6% hetastarch solutions, and crystalloid solutions, as well as undertakes various research programs for vision restoration and Demyelination. The company has collaboration with Orbit Biomedical, Ltd. BioTime, Inc. was founded in 1990 and is headquartered in Alameda, California.

Beat the Market (BTM) Rank^™

3.3 Analyst's Opinion

Consensus Rating
BioTime has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $4.00, BioTime has a potential upside of 339.6% from its current price of $0.91.
Amount of Analyst Coverage
BioTime has received no research coverage in the past 90 days.

2.6 Community Rank

Outperform Votes
BioTime has received 204 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
BioTime has received 195 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
BioTime has received 51.13% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about BioTime and other stocks. Vote “Outperform” if you believe BTX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe BTX will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
BioTime does not currently pay a dividend.
Dividend Growth
BioTime does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, BioTime insiders have not sold or bought any company stock.

0.0 Earnings and Valuation

Overall Beat the Market Rank^™

1.17 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN

Industry Biotechnology

Sub-IndustryBiotechnology

SectorMedical

Current SymbolNYSEAMERICAN:BTX

Previous SymbolNYSEMKT:BTX

CUSIP09066L10

CIK876343

Webwww.biotimeinc.com

Phone+1-510-5213390

Debt

Debt-to-Equity RatioN/A

Current RatioN/A

Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / Cash FlowN/A

Book ValueN/A

Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A

Net IncomeN/A

Net MarginsN/A

Return on EquityN/A

Return on AssetsN/A

Miscellaneous

Employees76

Outstanding Shares149,643,000

Market Cap$136.18 million

Next Earnings DateN/A

OptionableOptionable

Receive BTX News and Ratings via Email

Sign-up to receive the latest news and ratings for BTX and its competitors with MarketBeat's FREE daily newsletter.

BioTime (NYSEAMERICAN:BTX) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of BioTime?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioTime in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for BioTime.

How were BioTime's earnings last quarter?

BioTime, Inc. (NYSEAMERICAN:BTX) posted its quarterly earnings results on Tuesday, August, 9th. The biotechnology company reported ($0.11) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.17) by $0.06. The biotechnology company earned $1.27 million during the quarter, compared to the consensus estimate of $1.75 million. View BioTime's earnings history.

What price target have analysts set for BTX?

2 brokerages have issued 1-year target prices for BioTime's shares. Their forecasts range from $4.00 to $4.00. On average, they expect BioTime's stock price to reach $4.00 in the next twelve months. This suggests a possible upside of 339.6% from the stock's current price. View analysts' price targets for BioTime.

What are Wall Street analysts saying about BioTime stock?

Here are some recent quotes from research analysts about BioTime stock:

1. According to Zacks Investment Research, "BioTime, Inc. is a clinical-stage biotechnology company focused on developing and commercializing novel therapies in the field of regenerative medicine. The foundation of its core therapeutic technology platform is pluripotent cells that are capable of becoming any of the cell types in the human body. BioTime's research and other activities have resulted, over time, in the creation of other subsidiaries that address other non-therapeutic market opportunities such as cancer diagnostics, drug development and cell research products, and mobile health software applications. " (8/9/2019)
2. HC Wainwright analysts commented, "Valuation and risks to price target achievement. We reiterate our Buy rating and $4 price target. Our valuation is based on our clinical net present value (NPV) model, which allows us to flex multiple assumptions affecting a drug’s potential commercial profile. Our valuation is currently based on the opportunities for OpRegen (approximately 57% valuation contribution) on only the U.S. opportunity and Renevia (43% valuation contribution) in the E.U. We note that our current projected values for both these assets are based on minimal market penetration in very large markets." (8/9/2019)

Has BioTime been receiving favorable news coverage?

Media stories about BTX stock have been trending extremely positive on Thursday, according to InfoTrie Sentiment Analysis. The research group ranks the sentiment of media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. BioTime earned a coverage optimism score of 5.0 on InfoTrie's scale. They also gave media stories about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near future. View the latest news aboutBioTime.

Who are some of BioTime's key competitors?

Some companies that are related to BioTime include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Immunomedics (IMMU). View all competitors.

What other stocks do shareholders of BioTime own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioTime investors own include Geron (GERN), CA (CA), Asterias Biotherapeutics (AST), Micron Technology (MU), Endologix (ELGX), BlackRock (BLK), Opko Health (OPK), Immunomedics (IMMU), OncoCyte (OCX) and Synergy Pharmaceuticals (SGYP).

Who are BioTime's key executives?

BioTime's management team includes the following people:

Mr. William Annett, Pres & CEO of OncoCyte Corp. (Age 65)
Dr. Stephana E. Patton, Gen. Counsel, Corp. Sec. & Chief Compliance Officer (Age 48)
Mr. Brian M. Culley, CEO, Pres & Director (Age 48)
Ms. Brandi L. Roberts, CFO & Sec. (Age 45)
Ioana C. Hone, Director of Investor Relations

What is BioTime's stock symbol?

BioTime trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "BTX."

How do I buy shares of BioTime?

Shares of BTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is BioTime's stock price today?

One share of BTX stock can currently be purchased for approximately $0.91.

How big of a company is BioTime?

BioTime has a market capitalization of $136.18 million. BioTime employs 76 workers across the globe.

What is BioTime's official website?

The official website for BioTime is www.biotimeinc.com.

How can I contact BioTime?

BioTime's mailing address is 1010 Atlantic Ave Ste 102, ALAMEDA, CA 94501-1147, United States. The biotechnology company can be reached via phone at +1-510-5213390.

This page was last updated on 6/4/2020 by MarketBeat.com Staff